Innovative Approach to lung Cancer Therapy

Nanobiotix is making strides in cancer treatment with its investigational product, NBTXR3 (also known as JNJ-1900).Recent data from an ongoing Phase 1 study, conducted in collaboration with the MD Anderson Cancer Center at the University of Texas, reveals encouraging results for patients with locally advanced non-small cell lung cancer (NSCLC).

Study Highlights: Safety and Efficacy

The study focuses on patients who have already undergone multiple lines of treatment and are eligible for re-irradiation.The initial dose-escalation phase of the trial has been completed, demonstrating a favorable safety profile for NBTXR3 when activated by radiotherapy. This is crucial, as many advanced lung cancer patients have limited treatment options due to prior toxicities.

Dr. Saumil Gandhi,the lead investigator,is set to present thes findings at the upcoming European Congress on Lung Cancer 2025. The data, gathered from twelve patients, confirms the feasibility of injecting NBTXR3 in this patient population.

Promising Survival Data

Early survival data indicates encouraging outcomes.The study reported a local progression-free survival (LPFS) rate of 64% at 12 months, with a median LPFS of 18.6 months. Furthermore, the overall survival (OS) rate at 12 months was 83%, with a median OS of 30.2 months. These results suggest a potential benefit for patients with limited therapeutic alternatives.

These preliminary findings suggest that NBTXR3, when combined with radiotherapy, could offer a meaningful advancement in survival outcomes for patients with advanced NSCLC.
Dr. Saumil Gandhi, Lead Investigator

While these results are promising, its vital to note that this is still early data from a phase 1 study. Larger, randomized controlled trials will be needed to confirm these findings and establish the efficacy of NBTXR3 in this setting.

Next Steps in the Clinical Trial

With the dose-escalation phase successfully completed, the study has moved into the expansion phase.As of now, five of the twelve patients planned for this phase have already received injections. This expansion will provide further insights into the efficacy and safety of NBTXR3 in a larger patient cohort.

Lung cancer remains a notable global health challenge. according to the American Cancer Society, lung cancer is the leading cause of cancer death in the United States, accounting for approximately 25% of all cancer deaths. New treatment options like NBTXR3 are crucial for improving outcomes for patients with this devastating disease.